Review papers with raw data transparency

• Two ASO-release modalities are explicitly laid out, which addresses a key engineering uncertainty: whether release depends on NS3 protease activity/cleavage timing vs RNA-level self-cleavage.
• Genome-level integration is used to motivate co-packaging and sustained delivery via replication (self-amplifying cycle), instead of relying only on transient extracellular dosing.
• Safety-by-design attempt exists: miRNA-target site insertion is proposed to attenuate replication in non-permissive tissues, and the paper discusses regulatory/containment concepts for replication-competent CNS vectors.

• Feasibility gap: No experimental demonstration is provided that the engineered JEV can be made safely, packaged with the designed RNA cargo at sufficient fidelity, and released in neurons as intended.
• ASO chemistry mismatch risks: The paper proposes unmodified RNA ASO embedded in a replicating RNA virus. RNA stability, nuclease degradation, and polymerase compatibility are plausible bottlenecks; the Perspective itself flags these classes of problems as engineering hurdles (e.g., fidelity, release timing, structural integrity), but without data.
• Replication control uncertainty: Self-replication in CNS is intrinsically hard to “contain.” The miRNA-attenuation concept may be variable due to disease-state and individual heterogeneity, which the paper also acknowledges.
• Targeting specificity uncertainty: The proposed targeting depends on (i) JEV neurotropism, (ii) immune-cell trafficking assumptions, and (iii) miRNA expression patterns. Each is context-dependent and could vary across models and patients.
• RdRp error/fidelity drift: The paper highlights the lack of proofreading and discusses how mutational drift could undermine ASO specificity (a major conceptual failure mode), but again offers discussion rather than measurements.

1. No functional ASO liberation in neuronal contexts (NS3 cleavage or ribozyme excision fails, or produces fragments that cannot engage RNAi).
2. No mutant SOD1 transcript knockdown despite delivery (target engagement absent or too weak).
3. Unacceptable neurovirulence or inflammatory toxicity due to replication-competent JEV activity not adequately constrained by miRNA attenuation.
4. Uncontrolled systemic/bystander spread beyond intended CNS compartments.

The paper’s concept sits within a wider family of self-replicating RNA viral vector strategies, where key themes are (i) amplification for potency at lower doses, (ii) safety and delivery trade-offs, and (iii) immunogenicity and translation uncertainty. A review focused on self-replicating RNA viruses for vaccines similarly emphasizes safety/delivery/stability challenges and variable translation from models to humans.

Importantly, oncology- and vaccine-focused self-replicating systems are not identical to a CNS replication-competent JEV-ASO; but they do share the same broad “amplification vs safety/containment” tension—making the Perspective’s central risks plausible rather than automatically dismissible.

The platform idea is conceptually ambitious: it combines (1) viral genome programmability, (2) an RNAi-targeting ASO payload, (3) self-amplifying delivery, and (4) miRNA attenuation. The mechanistic design is internally structured and maps to real engineering levers (release modality, attenuation sites, genome placement). However, the scientific bar for a replication-competent CNS vector is extremely high, and the paper does not provide evidence that its critical risks—release fidelity, replication control, neurovirulence, immune responses, and ASO functional knockdown—are resolved.